FDA approves Evenity for osteoporosis

FDA approved Evenity romosozumab-aqqg from Amgen and UCB to treat osteoporosis in postmenopausal women at high risk of fracture. In January, an FDA advisory committee voted 18-1 in favor of the drug's approval (see "FDA Panel Backs Amgen's Evenity for Osteoporosis").

Evenity's label includes a black box warning describing risks of heart attack, stroke and cardiovascular death associated with its use, and says the drug should not be given to patients who have had a heart attack or stroke within the previous year...